Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly
Eli Lilly is slamming the Phase III door for the lead program out of its six-year-old pact with Nektar Therapeutics, after their partnered autoimmune drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.